Stanford University
Showing 21-30 of 36 Results
-
Michael L. Goris
Professor of Radiology (Nuclear Medicine), Emeritus
Current Research and Scholarly InterestsRadio-immunotherapy. Medical Imaging Processing. Quantification for diagnosis Clinical validations
-
Erin Elizabeth Grady
Clinical Professor, Radiology - Rad/Nuclear Medicine
BioErin Grady, MD, CCD, FACNM, FSNMMI is a nuclear medicine physician at Stanford Hospital and Clinics in Stanford, California. She is actively involved nationally in the SNMMI in multiple capacities including as a Director-at-Large on the SNMMI Board of Directors, chair of the Nuclear Medicine Program Directors, a member of the General Nuclear Medicine Council board, co-chair of the Government Relations Committee and a longstanding member of the Coding and Reimbursement Committee. In addition, she is a past chair of the American Board of Nuclear Medicine and has served on the board of appeals panel, review committee and milestone development committee for Nuclear Medicine and milestone revision committee for Nuclear Radiology at the ACGME. Her areas of research interest include quality, education, radiopharmaceutical therapy and finding answers to clinical questions that arise during the course of practice. She is passionate about education in nuclear medicine, nuclear medicine’s future and is a staunch advocate for patients.
-
Edward Graves
Associate Professor of Radiation Oncology (Radiation Physics) and, by courtesy, of Radiology (Molecular Imaging Program at Stanford)
Current Research and Scholarly InterestsApplications of molecular imaging in radiation therapy, development of hypoxia and radiosensitivity imaging techniques, small animal image-guided conformal radiotherapy, image processing and analysis.
-
Thomas Guenther
Postdoctoral Scholar, Molecular Imaging Program at Stanford
Current Research and Scholarly InterestsCurrent research projects include the development of:
1) Gastrin-releasing peptide receptor (GRPR) targeted radiotheranostics (Cu-64, Ga-68, Tb-161, Lu-177, amongst others)
2) Radiohybrid-based cholecystokinin-2 receptor (CCK-2R) targeted radiotheranostics (F-18, Lu-177)
3) Radiotherapeutics for targeted alpha-particle therapy
4) Radiotheranostics for novel targets
All projects have a strong focus on clinical translation